Is Personalized Medicine a Good Pill for Pharma Firms?
Health-care analysts Damien Conover and Karen Andersen review takeaways from the American Society of Clinical Oncology's annual meeting, including the impact of personalized medicine.
Damien Conover: Thanks for joining us. My name is Damien Conover. I'm the pharmaceutical analyst here at Morningstar, and I'm joined by biotechnology analyst, Karen Andersen. Karen just returned from the American Society of Clinical Oncology's annual meeting. Now, this is one of the most important medical meetings of the whole year, and it really revolves around cancer treatments. Karen, thanks for joining us.
Karen Andersen: Good to be here.
Damien Conover does not own (actual or beneficial) shares in any of the securities mentioned above. Find out about Morningstar’s editorial policies.